# Peripheral blood stem cell mobilisation and collection for transplant, in patients and donors

Source: https://onco.cc/protocols/stem-cell-mobilisation-and-collection/  
OnCo record `stem-cell-mobilisation-and-collection` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Stem cells for a transplant are usually collected from the blood rather than the bone marrow. Daily injections of a growth factor for about four to five days move stem cells out of the marrow into the blood, and a machine then filters them out over a few hours while the rest of the blood is returned. If too few cells appear in the blood, a second medicine called plerixafor can be added.

## Summary

The reader's own unit's policy comes first. Patients (autologous): G-CSF alone ('steady state', filgrastim 10 micrograms/kg/day under the skin, apheresis usually on day 5) for those needing no further chemotherapy, or chemotherapy plus G-CSF where tumour reduction or a high yield is needed (EBMT Handbook 2024); after chemotherapy the Handbook gives the approved filgrastim dose as 5 micrograms/kg/day, often rounded up to 5 to 10 in practice. The US filgrastim label gives 10 micrograms/kg/day for at least 4 days before the first apheresis and until the last. In myeloma, the US lenalidomide label says mobilisation should occur within 4 cycles of a lenalidomide-containing therapy. Monitor blood CD34 from day 4 to 5 of G-CSF at the latest, or when leucocytes recover after chemotherapy; start apheresis above 20 CD34 cells per microlitre. The Handbook gives the minimum dose for one autologous transplant as 2 million CD34 cells per kg (optimal 2.5 to 5 million) and for an allogeneic transplant 4 million per kg of the recipient (optimal 5 to 8 million). Poor mobilisation (about 15% of patients): the Handbook recommends plerixafor below 10 CD34 cells per microlitre on days 4 to 5, considers it between 10 and 20, and uses it as rescue if the first apheresis yields under a third of the goal; the US label sets no count threshold: plerixafor is indicated with filgrastim in non-Hodgkin lymphoma and myeloma, started after 4 days of filgrastim and given about 11 hours before each apheresis for up to 4 days, at 0.24 mg/kg (or a fixed 20 mg at 83 kg or less), not above 40 mg a day; when creatinine clearance is 50 mL/min or less the dose is reduced by one third to 0.16 mg/kg (or a fixed 13 mg at 83 kg or less) and should not exceed 27 mg a day. Motixafortide is a US-labelled alternative in myeloma. Donors (allogeneic): fitness is assessed by a physician who is not the patient's treating physician (WMDA 3.22.3.1); pregnancy test and haemoglobinopathy risk assessment before mobilisation (FACT-JACIE B6.3.5, B6.3.6); mobilising agents given under experienced supervision (B6.3.4); a central venous catheter only in exceptional, documented circumstances (WMDA 8.05.2); a session of no more than 5 hours and no more than two consecutive sessions (Handbook); follow-up contact for at least 10 years (WMDA 9.02). Plerixafor is not approved for healthy donors, and the US filgrastim label says mobilisation in healthy donors is not an approved indication. Left upper abdominal or shoulder pain during G-CSF needs assessment for splenic enlargement or rupture (label).

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: stem cell harvest; stem cell collection; PBSC mobilisation; PBSC collection; stem cell mobilization; leukapheresis for stem cells; G-CSF mobilisation; plerixafor; just-in-time plerixafor; poor mobiliser; CD34 target; peripheral blood stem cell donation; donating stem cells

## Connected records

- protocols: [Leukapheresis to collect T cells for CAR T-cell manufacture](https://onco.cc/protocols/car-t-apheresis/), [Stem cell transplant: conditioning, the low blood count phase and engraftment monitoring](https://onco.cc/protocols/hct-conditioning-and-engraftment-care/)
- technologies: [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/), [Apheresis and starting-material collection](https://onco.cc/technologies/apheresis-starting-material/), [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Growth factors: G-CSF and febrile neutropenia prevention](https://onco.cc/technologies/g-csf-growth-factors/)
- targets: [CD34](https://onco.cc/targets/cd34/)
- institutions: [Anthony Nolan](https://onco.cc/institutions/anthony-nolan/), [NMDP](https://onco.cc/institutions/nmdp/), [World Marrow Donor Association (WMDA)](https://onco.cc/institutions/wmda/)
- drugs: [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/), [Lenograstim](https://onco.cc/drugs/lenograstim/), [Motixafortide](https://onco.cc/drugs/motixafortide/), [Plerixafor](https://onco.cc/drugs/plerixafor/)
- terms: [Apheresis (leukapheresis)](https://onco.cc/terms/apheresis/)

---
JSON: https://onco.cc/api/v1/entities/stem-cell-mobilisation-and-collection.json